Quantcast
Last updated on April 23, 2014 at 17:00 EDT

Latest Metabolic Solutions Development Company LLC Stories

2013-09-19 12:28:38

New data suggests novel insulin sensitizer may prevent damage and death of nerve cells in the brain that control movement, balance, and walking KALAMAZOO, Mich., Sept. 19, 2013 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced today the presentation of new data showing an investigational drug being studied to treat diabetes, MSDC-0160, had a protective effect on nerve cells in the brain that control movement, balance and walking. These results in...

2013-09-09 08:26:20

Study suggests novel insulin sensitizer may prevent cognitive decline in people with Alzheimer's-related dementia KALAMAZOO, Mich., Sept. 9, 2013 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) has announced that Jerry Colca, PhD, co-founder and chief scientific officer of MSDC, will present results of a Phase 2a study on September 9 at the 14th International Conference on Alzheimer's Drug Discovery. In people with dementia due to Alzheimer's disease (AD) who...

2013-05-29 12:27:39

mTOT Modulators may provide a new tool for preserving beta-cell function in patients with type 2 diabetes KALAMAZOO, Mich., May 29, 2013 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced today the publication of data in a recent issue of the scientific journal PLOS ONE (http://dx.plos.org/10.1371/journal.pone.0062012) on the effects of a new drug for type 2 diabetes in restoring insulin sensitivity and insulin content in human beta- (b-) cells....

2013-05-15 16:25:33

Modulating mTOT may represent a new way forward to treat metabolic diseases associated with age-related mitochondrial dysfunction - especially insulin resistance and type 2 diabetes KALAMAZOO, Mich., May 15, 2013 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced today the publication of data in the latest issue of the scientific journal PLOS ONE (http://dx.plos.org/10.1371/journal.pone.0061551) on a new drug target for type 2 diabetes located in the inner...

2013-02-07 08:28:06

KALAMAZOO, Mich., Feb. 7, 2013 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced today that it has received an award from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to conduct preclinical research on a first-in-class mTOT Modulator, MSDC-0160, as a potential treatment for levodopa induced dyskinesia (LID). The study will be undertaken in collaboration with Patrik Brundin, MD, PhD, of Van Andel Institute (VAI). The aim of the study, titled...

2013-01-24 16:26:48

KALAMAZOO, Mich., Jan. 24, 2013 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced today the publication of data from a Phase 2b study of the company's prototype insulin sensitizer in patients diagnosed with type 2 diabetes. The data demonstrate MSDC-0160, a novel once-a-day oral insulin sensitizer and the first in a new class of therapeutic agents called mTOT Modulators(TM), met the study's primary endpoint of significantly reducing fasting plasma glucose (FPG) and...

2012-10-17 15:23:02

KALAMAZOO, Mich., Oct. 17, 2012 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) CEO Stephen Benoit will be presenting an overview of the company's business at the 2(nd) annual BIO Convention taking place October 24-25 in China. Hosted by the Biotechnology Industry Organization (BIO), the Convention will bring together executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia to meet and explore business opportunities...

2012-10-02 02:28:48

BERLIN, Oct. 2, 2012 /PRNewswire/ -- Researchers at Metabolic Solutions Development Company, LLC (MSDC) have identified a mitochondrial target through which insulin sensitizers achieve their anti-diabetic effects. New insights into this protein complex and its role in metabolic signaling are expected to enable the pursuit of alternative approaches to the discovery of novel, insulin sensitizing agents. Data supporting this finding are being presented today at the 48(th) Annual Meeting of the...

2012-09-07 14:21:39

KALAMAZOO, Mich., Sept. 7, 2012 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) will provide an update on the clinical evaluation of MSDC-0160, a first in class mTOT Modulator(TM) that is being investigated in an ongoing Phase 2a trial in subjects with mild to moderate dementia due to Alzheimer's disease. The update will be presented at the Alzheimer's Drug Discovery Foundation (ADDF) 13th International Conference on Alzheimer's Drug Discovery in Jersey City, NJ September...

2012-08-29 06:25:18

KALAMAZOO, Mich., Aug. 29, 2012 /PRNewswire/ -- Researchers at Metabolic Solutions Development Company, LLC (MSDC) have identified a mitochondrial protein complex through which insulin sensitizers achieve their anti-diabetic effects. Findings from this research are being presented August 30 at the Benzon Symposium No. 58 in Copenhagen, Denmark. The newly identified mitochondrial target is being referred to as the mitochondrial Target of Thiazolidinediones, or mTOT((TM)). Key...